The Innovative Health Initiative (IHI) is a joint undertaking between the European Union and industry associations representing the sectors involved in healthcare. The IHI is part of the Horizon Europe Framework Programme. IHI call 11 is a two-stage call with topics on brain dysfunction, the link between infections and non-communicable diseases, pharmacovigilance, type 1 diabetes, and ambulatory surgical centres.
Topic 1: Towards precision medicine: platform for transdiagnostic stratification of brain dysfunction. This IHI JU topic focuses on developing a platform that enables more precise and individualized treatments for brain disorders. The action generated by this topic is expected to contribute to all the following outcomes:
- A sustainable and collaborative large, multimodal data platform that can identify novel transdiagnostic candidate markers and endpoints for the symptom domains of reward/motivation (including anhedonia) and impulsivity (RM&I) in neuropsychiatric, neurodegenerative, and physical health disorders. Relevant disorders include Alzheimer’s disease (AD), major depressive disorder (MDD), and obesity (priority areas). Other relevant disorders/diseases include, but are not limited to, substance use and associated disorders, schizophrenia, bipolar disorder, borderline personality disorder, and Parkinson’s disease. For a disorder/disease to be relevant, there must be evidence to show that reward/motivation and/or impulsivity are clinically significant symptom domains;
- Novel transdiagnostic candidate markers and endpoints are identified and progressed towards validation. Learnings are applied in drug discovery to increase probability of success (PoS);
- A clear roadmap to achieve full validation of candidate markers and endpoints by regulatory and health technology assessment (HTA) bodies. Clinical best-practice guidelines are developed, and recommendations are made to the current diagnostic classifications1 to expedite the adoption of precision medicine;
- A greater understanding of the biological foundations of RM&I symptom domains and their role in AD, MDD, obesity, and other relevant disorders, enabling the generation of novel therapeutic approaches by industry;
- Closer alignment between psychiatry, neurology, and physical health disciplines to enable dialogue between healthcare professionals (HCPs) and other medical specialists to optimise outcomes, particularly for individuals with complex healthcare needs and comorbidities.
Applications are open to consortia of academic and industry partnerships in Europe and countries associated with the Horizon Europe program (such as Canada, Norway, the UK, and others), plus low and middle-income countries.
The IHI JU provides a maximum financial contribution of up to 20,202,000 EUR for this call.
Funding call: HORIZON-JU-IHI-2025-11-01-two-stage
Short proposals are due October 9, 2025. Full proposals due April 29, 2026.